Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- PE ratio
- —
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 853,100
- Avg volume
- 3,495,312
- Day's range
- $0.00 – $0.00
- Shares out
- —
- Stochastic %K
- 100%
- Beta
- —
- Analysts
- Strong Buy
- Price target
- —
Company profile
Enzolytics, Inc. a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, the co...
Show more
Enzolytics, Inc. a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, the company's proprietary cell line produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics, Inc. is based in Plano, Texas.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 972 292 9414
- Website
- https://enzolytics.com
- Address
- 2000 North Central Expressway, Plano, United States
Latest news
No headlines yet.
